ABSTRACT-Structure-activity relationship of the chicken calcitonin gene-related peptide (cCGRP) was investigated and compared with human-a-CGRP (hCGRP) and rat CGRP (rCGRP) in the perfused mesenteric vascular beds of rats. In precontracted mesenteric vascular beds, cCGRP, hCGRP and rCGRP produced a concentration-dependent vasodilation. The vasodilator activities of cCGRP and rCGRP were equipotent and more potent than that of hCGRP. (Ala2,')cCGRP and (Des-l-Ala)-a-deamino cCGRP were 100 and 10-fold less potent than cCGRP, respectively. However, cCGRP curves of rCGRP to the right, but both peptides did not affect the maximum response and vasodilator responses to isoproterenol, these peptides being equipotent an tagonists (pA2 values: 7.6 and 7.4). In rat brain membrane preparations, cCGRP and its fragments and analogues, except for cCGRP , competed for specific binding sites with [125I]-hCGRP. These results suggest that cCGRP has a potent vasodilator activity for which the disulfide bridge at position 2 and 7 of cCGRP is an important site and that position 37 is necessary for the binding of the peptide to the receptor. Also, cCGRP [8 37] is a competitive CGRP-receptor antagonist.
processing of the calcitonin gene (1, 2) , is widely distribut ed in the mammalian peripheral and central nervous sys tem (3, 4) . Because CGRP has a potent vasodilator effect (5) and acts as a vasodilator neurotransmitter (6) , this pep tide is considered to be involved in the control of the tone of resistance blood vessels (6) (7) (8) (9) . In addition, CGRP has a variety of biological actions such as hypotension (10) , cardiac acceleration (11, 12) , increase of regional blood flow (10, 12) , regulation of calcium metabolism (13) and insulin secretion (14) . Two forms of CGRP, a and j3 CGRP, have been isolated from human and rat tissue (15) . Chakder and Rattan (16) and Sasaki et al. (3) report ed that the efficacy or binding activity of the a-form of CGRP is similar to that of the p-form. However, Gardiner et al. (10) reported that the a-form of CGRP is predominately involved in vasodilator and hypotensive effects in vivo.
The human-a-CGRP (hCGRP) sequence consists of 37 amino acids with a disulfide bridge between positions 2 and 7 and a C-terminal phenylalanine amide residue. Chicken CGRP (cCGRP) differs from hCGRP by having 4 different amino acids at positions 3, 14, 15 and 23, and shows 90% homology with hCGRP. Calcitonin, which is also generated by the calcitonin gene, has been shown to exhibit species-related divergence in structure and biologi cal activity. Interestingly, salmon calcitonin, eel calcito nin and chicken calcitonin, which were obtained from ultimobranchial glands, has more potent bioactivity than mammalian calcitonins (17, 18) . Recently, the CGRP receptor has been classified into two subtypes, CGRPI and CGRP2. CGRPI receptors are widely distributed in the vascular system and central nervous system, while CGRP2 subtype was found only in the vas deferens (mouse and guinea pig) and the aorta (mouse) (19, 20) . In the present study, we compared the vasodilator effect of cCGRP with that of hCGRP and rat CGRP (rCGRP) in rat mesenteric vascular beds. In addition, we investigated the structure-activity relationship of cCGRP in the rat mesenteric and rat brain membrane preparations, using analogues and fragments of cCGRP as shown in Fig. 1 . Fig. 1 . The amino acid sequences of cCGRP, hCGRP, rCGRP, cCGRP , hCGRP , (des-1-Ala)-a-deamino cCGRP, (Ala2'7)cCGRP and cCGRP . The differences in amino acid residues as compared to the sequence of cCGRP are indicated by the underlines.
MATERIALS AND METHODS

Perfusion of mesenteric vascular beds
The mesenteric vascular bed was isolated from male Wistar rats (350-400 g) under pentobarbital-Na (50 mg/kg, i.p.) anesthesia, and prepared for perfusion according to the previously described method (7) . The preparation was placed in a water-jacked organ bath maintained at 371C and perfused with a modified (see below) Krebs-Ringer bi carbonate solution (Krebs solution) at the constant flow rate of 5 ml/min by a peristaltic pump (SJ-1215; ATTO, Tokyo) and superfused with the same solution to prevent drying. The Krebs solution was bubbled with 95% 02 plus 5% CO2. The modified Krebs solution had the following composition: 120 mM NaCI, 5.0 mM KCI, 2.4 mM CaC12 1.2 mM MgSO4i 25.0 mM NaHCO3, 0.027 mM EDTA 2Na and 11.0 mM glucose. Changes in the perfusion pressure were measured by a pressure transducer (MPU 0.5A; Nihon Kohden, Tokyo) and recorded on an elec tronic recorder (R-62; Rikadenki, Tokyo).
After the basal perfusion pressure was stabilized, the preparation was perfused with Krebs solution containing methoxamine (7,uM) to produce the active tone. Gua nethidine (5 uM) was perfused simultaneously to block the adrenergic neurotransmission. The final concentration of each peptide was made by dilution of Krebs solution con taining methoxamine plus guanethidine and perfused. The concentration of the peptide was switched to a higher one when the vasodilation has reached a steady state (about 10 min). Vasodilator activity of the peptide was ex pressed as the pD2 value that was defined as the molar con centration producing 50% of the maximum response (21) .
To examine the effect of hCGRP [8 37] [8 37] were calculated by the method described by Van Rossum (21) . The slope of the antagonist was calculated from the Schild plot. At the end of each experiment, 100 pM papaverine was perfused through the preparation to produce a complete relaxation. Vasodilator activity is ex pressed as the percentage of the perfusion pressure at max imum relaxation induced by papaverine.
CGRP receptor binding studies
Experiments for radioligand-receptor binding in rat brain membrane preparations from male Wistar rats (150-300 g) were carried out as described previously (22) . Rat brain membranes homogenized with a teflon-glass homogenizer in 20 volumes of ice-cold buffer A (0.1 M Tris-HC1, 5.0 mM MgC12, 100.0 mM sucrose and 2.0 mM EGTA, pH 7.2, containing 0.1 mg/ml of bacitracin and 0.2% bovine serum albumin (BSA)). The homogenate was centrifuged (1000 x g, 10 min, 41C), and the supernatant obtained was recentrifuged (3000 x g, 20 min, 41C). The final pellet was resuspended in 10 volumes of ice-cold buffer A containing 0.8% BSA (buffer B), homogenized and used in the receptor binding assay. The receptor bind ing assay on membranes was performed as follows: A 100-pl aliquot of the receptor preparation in buffer B was 
Statistical analyses
All data were expressed as the means ±S.E.M. Statisti cal analyses were performed by one way analysis of vari ance followed by Tukey test. Parameters of the Schild plot used to calculate the pA2 values were obtained graphi cally by linear regression (21) . A P value <0.05 was regarded as significant. 
RESULTS
Vasodilator effects of cCGRP, hCGRP, rCGRP and ana logues or fragments of cCGRP In the perfused mesenteric vascular bed with active tone produced by 7 pM methoxamine plus 5 pM gua nethidine, perfusion of cCGRP, hCGRP and rCGRP produced a concentration-dependent fall in perfusion pressure due to vasodilation. The vasodilator activities of cCGRP and rCGRP were equipotent and more potent than that of hCGRP ( Fig. 2 and Table 1 ).
The perfusion of (des-l-Ala)-a-deamino cCGRP caused marked vasodilation that was as potent as hCGRP and tenfold less potent than cCGRP and rCGRP (Figs. 2  and 3 ). The vasodilator effect of (Ala2,')cCGRP was 100 fold less potent than cCGRP (Fig. 3) . The cCGRP had a very weak vasodilator effect (Fig. 3) . The C-termi nal fragment of cCGRP, cCGRP , caused further elevation of the perfusion pressure (Fig. 3) . Effects of cCGRP[8-371 and hCGRP on the vaso dilation induced by isoproterenol
In the perfused mesenteric vascular bed with active tone produced by 7 tiM methoxamine plus 5 pM gua nethidine, perfusion of isoproterenol (0.1 3000 nM) produced a concentration-dependent vasodilation. Com bined perfusion of isoproterenol and cCGRP [8 37 ] (0.1 and 1 pM) or hCGRP [8 37 ] (0.1 and 1 pM) did not modi fy the concentration-response curve of the vasodilator effects of isoproterenol (Fig. 4, B and D) .
Effects of cCGRP, hCGRP, cCGRP , hCGRP 
DISCUSSION
In the present study, we demonstrated that cCGRP, rCGRP and hCGRP produced a concentration-depend ent vasodilator effect in the perfused rat mesenteric vas cular bed with active tone. The vasodilator effect of cCGRP was 10 times more potent than that of hCGRP and similar to that of rCGRP. As shown in Fig. 1 , the differences in amino acid residues between cCGRP and hCGRP are at positions 3, 14, 15 and 23; those between cCGRP and rCGRP are at positions 1, 14, 15, 23, 25 and 35; and those between rCGRP and hCGRP at positions 1, 3, 25 and 35. Because the vasodilator activities of cCGRP and rCGRP are greater than that of hCGRP, the 3rd amino acid residue (asparagine in the human peptide and aspartic acid in the chicken and rat peptides) may play an important role in vasodilator activity. Similar difference in hypocalcemic activity between cCGRP and hCGRP has been reported in rats in vivo (13) . Furthermore, in cCGRP, the replacement of aspartic acid at position 14 by glycine, which is the corresponding amino acid for hCGRP, has been shown to reduce the hypocalcemic activity, while the replacement of glycine at position 14 of hCGRP with aspartic acid increased the activity (13) . Therefore, aspartic acid at position 14 may also be im portant for the biological activity of this peptide.
The CGRP has a disulfide bridge between cysteines at positions 2 and 7, and this site has been shown to be im portant in the production of certain biological responses such as hypocalcemia (13) and cardiac acceleration (12, 19) . The present study showed that (Ala2'')cCGRP in which cysteined at positions 2 and 7 are substituted by ala nine, thereby having no disulfide bridge, had a very weak vasodilator effect, indicating that the disulfide bridge is es or hCGRP . 0, A: responses in the presence of 0.1 and 1 1M of cCGRP or hCGRP , respectively. Insets show the Schild plot analysis with a fitted line for cCGRP and hCGRP . Inset abscissa: concentration of cCGRP or hCGRP (nM). Each value shows the mean±S.E.M. for 4-6 experiments. sential for inducing the vasorelaxation. On the contrary, (des-1-Ala)-a-deamino cCGRP, which conserves the di sulfide bridge but has no a-amino group in its N-terminal, caused a potent and long-lasting vasodilator response, similar to cCGRP and rCGRP. The removal of the a amino group in the N-terminal has been shown to confer resistance against aminopeptidase (13) . Therefore, (des 1-Ala)-a-deamino cCGRP may have induced stronger vasodilation by resisting degradation by aminopeptidase.
The C-terminal fragment of cCGRP, cCGRP , which lacks amino acid residues at positions 1 to 7, caused a vasoconstrictor response instead of vasodilation. A similar analogue, hCGRP , has been reported to act as a selective and competitive antagonist of CGRP receptors (23, 24) . In the present study, cCGRP , like hCGRP , inhibited the vasodilator response induced by native rCGRP and caused a parallel shift of the concentration-response curves for rCGRP to the right without changing the maximal response, suggesting that the nature of the antagonism is competitive. Both cCGRP These results strongly suggest that cCGRP [8 37 ] as well as hCGRP [8 37 ] are selective and competitive antagonists of CGRP receptors. The CGRP receptor has been classified into CGRP1 and CGRP2 subtypes (19, 20) . The hCGRP [8 37 ] has been shown to be an antagonist for CGRP 1 receptors (19, 20) . Therefore, cCGRP is also likely to be an antagonist for the CGRP1 subtype.
We have reported that the rat mesenteric vascular bed preparation is innervated by CGRP-containing vaso dilator nerves (6) (7) (8) (9) . Periarterial nerve stimulation of the preparation produces the neurogenic vasodilator response and release of CGRP in the perfusate (9, 25) . The hCGRP [8 37 ] inhibits the neurogenic vasodilator response in the mesenteric vascular bed (9, 24) , indicating that the response is mediated by endogenous CGRP that is released from CGRP-containing vasodilator nerves. Furthermore, the spontaneous release of CGRP has been detected in the perfused mesenteric vascular bed. There fore, the vasoconstrictor response induced by cCGRP [8 37 ] demonstrated in this study may be a result of the inhibitory effects of vasodilation of endogenous CGRP.
The N-terminal fragment of cCGRP, cCGRP [l -36] , that lacks phenylalanine amide at position 37, produced little or no vasodilator response. Because this fragment conserves a disulfide bridge at positions 2 and 7, the lack of a vasodilator effect may be due to the loss of the bind ing to the CGRP receptor. This concept is supported by the findings that cCGRP[l -36] displayed little affinity for the [1251]-hCGRP binding site in rat membrane prepa rations. Similar findings that various N-terminal frag ments without phenylalanine amide at position 37 had no biological activity have been reported in the guinea pig atria and rat vas deferens (19) . In contrast, the C-terminal fragment showed relatively high affinity for the [125I] hCGRP binding site, although the potency was less than those of native cCGRP and hCGRP. Thus, it is very like ly that the disulfide bridge between positions 2 and 7 is essential for vasodilator activity, and the C-terminal phen ylalanine at position 37 is important in the binding of CGRP to the receptor.
In conclusion, the present results suggest that cCGRP as well as rCGRP and hCGRP has a potent vasodilator effect in the rat mesenteric resistance vessels. It is also sug gested that the C-terminal fragment of cCGRP, cCGRP [8 37] , is a competitive antagonist for CGRP receptors, especially the CGRP1 subtype, and is useful for studying the role of endogenous CGRP in the cardiovascular con trol.
